Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide …

PB Nielsen, F Skjøth, M Søgaard, JN Kjældgaard… - bmj, 2017 - bmj.com
Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110
mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation …
被引用次数：390 相关文章

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide …

PB Nielsen, F Skjøth, M Søgaard… - BMJ (Clinical …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110
mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation …

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation

PB Nielsen, F Skjøth, M Søgaard, JN Kjældgaard… - BMJ: British Medical …, 2017 - JSTOR
OBJECTIVE To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran
110 mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial …
[HTML] nih.gov

[HTML][HTML] Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted …

PB Nielsen, F Skjøth, M Søgaard, JN Kjældgaard… - The BMJ, 2017 - ncbi.nlm.nih.gov
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and
warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study - PMC …

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide …

PB Nielsen, F Skjøth, M Søgaard… - BMJ: British Medical …, 2017 - search.proquest.com
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and
warfarin in patients with atrial fibri Page 1 the bmj | BMJ 2017;356:j510 | doi: 10.1136/bmj.j510 …

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide …

PB Nielsen, F Skjøth, M Søgaard… - … (Clinical Research ed …, 2017 - europepmc.org
Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110
mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation …
[PDF] birmingham.ac.uk

[PDF][PDF] Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation

PB Nielsen, F Skjøth, M Søgaard, JN Kjældgaard… - bmj, 2017 - research.birmingham.ac.uk
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and
warfarin in patients with atrial fibri Page 1 University of Birmingham Effectiveness and safety …

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide …

PB Nielsen, F Skjøth, M Søgaard, JN Kjældgaard… - The BMJ, 2017 - vbn.aau.dk
Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110
mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation …
[PDF] bham.ac.uk

[PDF][PDF] Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation

PB Nielsen, F Skjøth, M Søgaard, JN Kjældgaard, G Lip… - bmj, 2017 - pure-oai.bham.ac.uk
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and
warfarin in patients with atrial fibri Page 1 University of Birmingham Effectiveness and safety …

[引用][C] Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted …

PB Nielsen, F Skjøth, M Søgaard, JN Kjældgaard… - BMJ, 2017 - cir.nii.ac.jp
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and
warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study | CiNii …